Kinetic analysis and binding studies of a new recombinant human factor VIIa for treatment of haemophilia.
about
PERSEPT 1: a phase 3 trial of activated eptacog beta for on-demand treatment of haemophilia inhibitor-related bleeding.Safety and dose-dependency of eptacog beta (activated) in a dose escalation study of non-bleeding congenital haemophilia A or B patients, with or without inhibitors.A promising on-demand treatment option for bleeding events in haemophilia patients with inhibitors.
P2860
Kinetic analysis and binding studies of a new recombinant human factor VIIa for treatment of haemophilia.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
Kinetic analysis and binding s ...... for treatment of haemophilia.
@en
Kinetic analysis and binding s ...... for treatment of haemophilia.
@nl
type
label
Kinetic analysis and binding s ...... for treatment of haemophilia.
@en
Kinetic analysis and binding s ...... for treatment of haemophilia.
@nl
prefLabel
Kinetic analysis and binding s ...... for treatment of haemophilia.
@en
Kinetic analysis and binding s ...... for treatment of haemophilia.
@nl
P2860
P356
P1433
P1476
Kinetic analysis and binding s ...... for treatment of haemophilia.
@en
P2093
P2860
P304
P356
10.1111/HAE.13110
P577
2016-12-19T00:00:00Z